MCID: HYP082
MIFTS: 43

Hypopharynx Cancer

Categories: Bone diseases, Cancer diseases, Gastrointestinal diseases, Oral diseases, Rare diseases

Aliases & Classifications for Hypopharynx Cancer

MalaCards integrated aliases for Hypopharynx Cancer:

Name: Hypopharynx Cancer 12 15
Hypopharyngeal Cancer 12 53 55 73
Hypopharyngeal Neoplasms 44 73
Malignant Neoplasm of Ill-Defined Sites Within the Lip and Oral Cavity 12
Malignant Neoplasm of Other Specified Sites of Hypopharynx 12
Malignant Neoplasm of Other Specified Hypopharyngeal Site 12
Malignant Neoplasm of Posterior Hypopharyngeal Wall 12
Malignant Neoplasm of Posterior Wall of Hypopharynx 12
Malignant Tumor of Posterior Wall of Hypopharynx 12
Malignant Neoplasm of Hypopharynx 12
Malignant Tumour of Hypopharynx 12
Malignant Hypopharyngeal Tumor 12
Malignant Tumor of Hypopharynx 12
Hypopharyngeal Carcinoma 73

Classifications:



External Ids:

Disease Ontology 12 DOID:8533
ICD9CM 35 148 148.3 148.9
MeSH 44 D007012
NCIt 50 C7190
SNOMED-CT 68 93831006 93968005

Summaries for Hypopharynx Cancer

Disease Ontology : 12 A pharynx cancer that is located in the hypopharynx.

MalaCards based summary : Hypopharynx Cancer, also known as hypopharyngeal cancer, is related to esophageal cancer and postcricoid region cancer. An important gene associated with Hypopharynx Cancer is MIR489 (MicroRNA 489), and among its related pathways/superpathways is Abacavir Pathway, Pharmacokinetics/Pharmacodynamics. The drugs Dopamine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include lymph node, testes and lung.

Related Diseases for Hypopharynx Cancer

Diseases related to Hypopharynx Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
# Related Disease Score Top Affiliating Genes
1 esophageal cancer 10.3
2 postcricoid region cancer 10.3
3 aryepiglottic fold cancer 10.3
4 dysphagia 10.1
5 anal canal carcinoma 10.1 CD6 NME1
6 pharynx cancer 10.1 CD6 SMUG1
7 laryngeal disease 10.1 CD6 NME1
8 anus cancer 10.1 CD6 SMUG1
9 esophageal disease 10.0 ADH1B SMUG1
10 oropharynx cancer 10.0 CD6 SMUG1
11 nasopharyngeal disease 10.0 CD6 SMUG1
12 connective tissue cancer 10.0 AREG SMUG1
13 squamous cell carcinoma 10.0
14 cervix disease 10.0 AREG SMUG1
15 uterine anomalies 10.0 AREG SMUG1
16 respiratory system cancer 10.0 AREG MET SMUG1
17 gastrointestinal system cancer 10.0 AREG MET SMUG1
18 pancreas adenocarcinoma 9.9 AREG MET SMUG1
19 salivary gland carcinoma 9.9 AREG MET
20 gastric adenocarcinoma 9.9 MET NME1 SMUG1
21 stomach disease 9.9 AREG MET
22 amyotrophic lateral sclerosis 1 9.9
23 prostate cancer 9.9
24 small cell cancer of the lung 9.9
25 down syndrome 9.9
26 lung cancer 9.9
27 polyarteritis nodosa, childhood-onset 9.9
28 colitis 9.9
29 thrombosis 9.9
30 hypothyroidism 9.9
31 thyroid cancer 9.9
32 lateral sclerosis 9.9
33 spondylitis 9.9
34 boerhaave syndrome 9.9
35 syndrome of inappropriate antidiuretic hormone 9.9
36 paraneoplastic syndromes 9.9
37 cardiogenic shock 9.9
38 laryngeal cleft 9.8
39 oropharyngeal cancer, adult 9.8
40 large intestine cancer 9.8 AREG MET NME1 SMUG1

Comorbidity relations with Hypopharynx Cancer via Phenotypic Disease Network (PDN):


Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Hypopharynx Cancer:



Diseases related to Hypopharynx Cancer

Symptoms & Phenotypes for Hypopharynx Cancer

Drugs & Therapeutics for Hypopharynx Cancer

Drugs for Hypopharynx Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 126)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
2
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
3
Nicotine Approved Phase 4,Not Applicable 54-11-5 942 89594
4 Liver Extracts Phase 4,Phase 2,Not Applicable
5 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 2
6 Antidepressive Agents Phase 4,Phase 2
7 Antidepressive Agents, Second-Generation Phase 4,Phase 2
8 Dopamine Uptake Inhibitors Phase 4,Phase 2
9 Neurotransmitter Uptake Inhibitors Phase 4,Phase 2
10 Psychotropic Drugs Phase 4,Phase 2
11 Dopamine Agents Phase 4,Phase 2
12 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
13 Neurotransmitter Agents Phase 4,Phase 2,Phase 3,Not Applicable
14 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Not Applicable
15 Nicotinic Agonists Phase 4,Not Applicable
16 Cholinergic Agents Phase 4,Phase 2,Phase 3,Not Applicable
17 Autonomic Agents Phase 4,Phase 2,Phase 3,Not Applicable
18 Central Nervous System Stimulants Phase 4,Not Applicable
19
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
20
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
21
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1 114977-28-5 148124
22
Carboplatin Approved Phase 3 41575-94-4 10339178 38904 498142
23
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
24 Kava Approved, Investigational, Nutraceutical Phase 3 9000-38-8
25 Pharmaceutical Solutions Phase 3
26 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
27 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
28 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
29 Immunologic Factors Phase 3,Phase 2,Phase 1
30 Antimetabolites Phase 3,Phase 2,Phase 1
31 Muscarinic Agonists Phase 2, Phase 3
32 Immunoglobulins Phase 3,Phase 2,Phase 1
33 Antibodies Phase 3,Phase 2,Phase 1
34
Amifostine Approved, Investigational Phase 2,Phase 1 20537-88-6 2141
35
Paclitaxel Approved, Vet_approved Phase 1, Phase 2,Phase 2,Not Applicable 33069-62-4 36314
36
Gemcitabine Approved Phase 1, Phase 2 95058-81-4 60750
37
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
38
Indinavir Approved Phase 2 150378-17-9 5362440
39
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
40
Hydroxyurea Approved Phase 1, Phase 2,Phase 2 127-07-1 3657
41 Raspberry Approved Phase 1, Phase 2
42
Trioxsalen Approved Phase 2 3902-71-4 5585
43
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
44
Zinc Approved, Investigational Phase 2 7440-66-6
45
Zinc oxide Approved Phase 2 1314-13-2
46
Pregabalin Approved, Illicit, Investigational Phase 2 148553-50-8 5486971
47
Pembrolizumab Approved Phase 2,Phase 1 1374853-91-4
48
Eniluracil Investigational Phase 1, Phase 2 59989-18-3
49 Radiation-Protective Agents Phase 2,Phase 1
50 Protective Agents Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 84)
# Name Status NCT ID Phase Drugs
1 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
2 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
3 Parotid-Sparing Intensity-Modulated Radiation Therapy Compared With Conventional Radiation Therapy in Treating Patients With Oropharyngeal or Hypopharyngeal Cancer Who Are at High Risk of Radiation-Induced Xerostomia Unknown status NCT00081029 Phase 3
4 Iseganan Hydrochloride in Preventing Oral Mucositis in Patients Who Are Undergoing Radiation Therapy for Head and Neck Cancer Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
5 Induction CT by Cisplatin, 5FU With or Without Docetaxel in Patients With T3 and T4 Larynx and Hypopharynx Carcinoma Completed NCT00169182 Phase 3 DOCETAXEL
6 Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
7 Accelerated Radiotherapy and Concomitant Chemo-radiotherapy in HNSCC Completed NCT00158652 Phase 3 5FU, Paraplatin
8 Sargramostim in Decreasing Mucositis in Patients Receiving Radiation Therapy for Head and Neck Cancer Completed NCT00008398 Phase 3
9 Acupuncture-Like Transcutaneous Electrical Nerve Stimulation (ALTENS) or Pilocarpine in Treating Early Dry Mouth in Patients Undergoing Radiation Therapy for Head and Neck Cancer Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
10 Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection Recruiting NCT02918955 Phase 3 Chemotherapy (Cisplatin)
11 IMRT Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Stage III-IV HNSCC Active, not recruiting NCT00158678 Phase 3 concomitant cisplatin
12 Concurrent Chemoradiation Versus Surgery With Adjuvant Therapy in Advanced Laryngopharyngeal Cancers Terminated NCT00128817 Phase 3
13 Prevention of Radiation-induced Severe Oral Mucositis in Oral Cavity, Oropharynx, Hypopharynx, and Cavum Cancer Terminated NCT01066741 Phase 3 Homeodent®;1.4% Sodium Bicarbonate solution
14 Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients Who Have Undergone Surgery for Advanced Hypopharyngeal Cancer, Oropharyngeal Cancer, Laryngeal Cancer, or Oral Cavity Cancer at High Risk of Recurrence Withdrawn NCT01142414 Phase 3 cisplatin;fluorouracil
15 Safety and Efficacy Study of Nimotuzumab Plus Neoadjuvant and Concurrent Chemoradiotherapy to Treat Oropharynx and Hypopharynx Cancer Unknown status NCT01516996 Phase 2 docetaxel and cisplatin
16 Neoadjuvant Chemotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck (SCCHN) Unknown status NCT01312350 Phase 2 neoadjuvant docetaxel/cisplatin/fluorouracil;No treatment before definitive CCRT
17 Surgery, Radiation Therapy, and Combination Chemotherapy in Treating Patients With Recurrent Head and Neck Cancer Unknown status NCT00003777 Phase 2 amifostine trihydrate;cisplatin;fluorouracil
18 Amifostine Plus Chemotherapy and Radiation Therapy in Treating Patients With Advanced, Unresectable Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
19 Cisplatin and Gemcitabine in Treating Patients With Advanced Squamous Cell Cancer of the Head and Neck Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
20 Paclitaxel in Treating Patients With Recurrent or Refractory Head and Neck Cancer Unknown status NCT00003327 Phase 2 paclitaxel
21 External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
22 Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation Completed NCT00169247 Phase 2 cetuximab;Cisplatin
23 Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer Completed NCT02075385 Phase 2
24 Docetaxel and Radiation Therapy in Treating Patients With Stage II or Stage III Cancer of the Larynx or Hypopharynx Completed NCT00243113 Phase 2 docetaxel
25 A Phase I/II Study of the Use of Intensity Modulated Radiotherapy (IMRT) in Cancer of the Thyroid, Larynx and Hypopharynx Completed NCT02055989 Phase 1, Phase 2
26 A Phase II Study In Patients With Advanced Head And Neck Cancer Of Standard Chemoradiation And Add-On Cetuximab Completed NCT01435252 Phase 2 Cetuximab
27 Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Completed NCT00833261 Phase 2 cetuximab;cisplatin
28 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced Mouth Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
29 Phase 1b Food Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer. Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
30 Porfimer Sodium in Diagnosing Patients With Head and Neck Cancer Completed NCT00002964 Phase 2 porfimer sodium
31 Celecoxib in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia Completed NCT00101335 Phase 2 celecoxib
32 Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer Completed NCT00002951 Phase 2 fluorouracil;hydroxyurea
33 Cetuximab in Treating Patients With Precancerous Lesions of the Upper Aerodigestive Tract Completed NCT00524017 Phase 2
34 Celecoxib in Preventing Cancer in Patients With Oral Leukoplakia and/or Head and Neck Dysplasia Completed NCT00052611 Phase 2 Celecoxib
35 Bupropion in Helping Adults Stop Smoking Completed NCT00534001 Phase 2 bupropion hydrochloride
36 Zinc Supplements in Lowering Cadmium Levels in Smokers Completed NCT00376987 Phase 2
37 New Strategy of Improving Treatment Outcome and Larynx-preservation Rate in Locally Advanced Hypopharyngeal Carcinoma Recruiting NCT03558035 Phase 2 Induction CT+ CRT group
38 Dose Escalation Versus Standard in Laryngopharyngeal Cancers Recruiting NCT02757222 Phase 1, Phase 2
39 Interest of Pregabalin (Lyrica) on the Treatment of Reflex Earache in Head and Neck Cancer. Recruiting NCT02924675 Phase 2 Pregabalin;Placebo
40 Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Recruiting NCT03082534 Phase 2 Pembrolizumab, Cetuximab
41 Adaptive Radiotherapy for Head and Neck Cancer Recruiting NCT03096808 Phase 2
42 18F FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy Active, not recruiting NCT01806675 Phase 1, Phase 2 fludeoxyglucose F 18;2-fluoropropionyl-labeled pegylated dimeric RGD peptide
43 Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer Terminated NCT00003489 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
44 Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Advanced and/or Recurrent Head and Neck Cancer Unknown status NCT00004097 Phase 1 fluorouracil;gemcitabine hydrochloride;paclitaxel
45 Photodynamic Therapy in Treating Patients With Premalignant or Early Stage Head and Neck Tumors Unknown status NCT00978081 Phase 1 aminolevulinic acid hydrochloride
46 Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors Completed NCT01172028 Phase 1 Taxotere (Docetaxel);Alimta (Pemetrexed)
47 Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
48 L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors Completed NCT00003430 Phase 1 L-778,123
49 SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck Completed NCT00005647 Phase 1 paclitaxel;semaxanib
50 Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck Active, not recruiting NCT02113878 Phase 1 BKM120;Cisplatin

Search NIH Clinical Center for Hypopharynx Cancer

Cochrane evidence based reviews: hypopharyngeal neoplasms

Genetic Tests for Hypopharynx Cancer

Anatomical Context for Hypopharynx Cancer

MalaCards organs/tissues related to Hypopharynx Cancer:

41
Lymph Node, Testes, Lung, Liver, Prostate, Cervix, Thyroid

The Foundational Model of Anatomy Ontology organs/tissues related to Hypopharynx Cancer:

19
The Hypopharynx

Publications for Hypopharynx Cancer

Articles related to Hypopharynx Cancer:

(show top 50) (show all 340)
# Title Authors Year
1
CircRNA-associated ceRNA network reveals ErbB and Hippo signaling pathways in hypopharyngeal cancer. ( 30365065 )
2019
2
Association of eIF4E and SPARC Expression with Lymphangiogenesis and Lymph Node Metastasis in Hypopharyngeal Cancer. ( 29374693 )
2018
3
Boerhaave syndrome due to hypopharyngeal stenosis associated with chemoradiotherapy for hypopharyngeal cancer: a case report. ( 29884971 )
2018
4
Trends in treatment, incidence and survival of hypopharynx cancer: a 20-year population-based study in the Netherlands. ( 29080963 )
2018
5
Verification of HE-based CTV in laryngeal and hypopharyngeal cancer using pan-cytokeratin. ( 30094352 )
2018
6
A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer. ( 29086129 )
2018
7
Hypopharyngeal cancer associated with synchronous oesophageal cancer: risk factors and benefits of image-enhanced endoscopic screening. ( 29237517 )
2018
8
Expression of PD-L1 on Immune Cells Shows Better Prognosis in Laryngeal, Oropharygeal, and Hypopharyngeal Cancer. ( 29271789 )
2018
9
Impact of alcohol dehydrogenase-aldehyde dehydrogenase polymorphism on clinical outcome in patients with hypopharyngeal cancer. ( 29286190 )
2018
10
Comparison of xerostomia incidence after three-dimensional conformal radiation therapy and contralateral superficial lobe parotid-sparing intensity-modulated radiotherapy for oropharyngeal and hypopharyngeal cancer. ( 29397249 )
2018
11
Combined transoral-transhyoid endoscopic approach for hypopharyngeal cancer. ( 29402609 )
2018
12
Postoperative mechanical bowel obstruction after pharyngolaryngectomy for hypopharyngeal cancer: Retrospective analysis using a Japanese inpatient database. ( 29537633 )
2018
13
Oncological and Functional Evaluation of Open Conservation Surgery for Hypopharyngeal Cancer with/without Reconstruction. ( 29780420 )
2018
14
To do or not to do: salvage management for hypopharyngeal cancer after chemoradiation therapy. ( 29926175 )
2018
15
Staging of Laryngeal and Hypopharyngeal Cancer: Computed Tomography versus Histopathology. ( 30083524 )
2018
16
Overexpression of miRNA 4451 is Associated With a Poor Survival of Patients With Hypopharyngeal Cancer After Surgery With Postoperative Radiotherapy. ( 30103154 )
2018
17
Comparison between open partial laryngectomy with tube-free tracheostomy and total laryngectomy for hypopharyngeal cancer with cartilage invasion. ( 30250561 )
2018
18
Prognostic nutritional index relevance in chemoradiotherapy for advanced oral cavity, oropharyngeal and hypopharyngeal cancer. ( 30272847 )
2018
19
Radiotherapy modality as a predictor of survival in hypopharyngeal cancer. ( 30306665 )
2018
20
Optimal timing for salvage surgery after definitive radiotherapy in hypopharyngeal cancer. ( 30309210 )
2018
21
Hypopharyngeal Cancer Treatment Delays: Benchmarks and Survival Association. ( 30324861 )
2018
22
Surgically-Treated Locoregionally Advanced Hypopharyngeal Cancer: Outcomes. ( 30357103 )
2018
23
Hypopharyngeal cancer: A state of the art review. ( 30409307 )
2018
24
Induction chemotherapy (IC) followed by radiotherapy (RT) versus cetuximab plus IC and RT in advanced laryngeal/hypopharyngeal cancer resectable only by total laryngectomy-final results of the larynx organ preservation trial DeLOS-II. ( 30412221 )
2018
25
Surgery vs. radiotherapy for locally advanced hypopharyngeal cancer in the contemporary era: A population-based study. ( 30479063 )
2018
26
Open-neck organ preservation surgery for hypopharyngeal cancer: indications, techniques, limits, and outcomes. ( 30507694 )
2018
27
Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography evaluation using metabolic tumor volume of the primary tumor and lymph nodes in advanced hypopharyngeal cancer. ( 30536887 )
2018
28
Prognostic value of metabolic tumor burden calculated using dual-time-point 18F-fluorodeoxyglucose positron emission tomography/CT in patients with oropharyngeal or hypopharyngeal cancer. ( 30537436 )
2018
29
Transoral laser microsurgery as standard approach to hypopharyngeal cancer. Survival analysis in a hospital based population. ( 28190450 )
2018
30
Sequential four-drug chemotherapy and intensity-modulated radiotherapy for larynx preservation in resectable advanced larynx and hypopharynx cancer: A pilot study. ( 27825651 )
2017
31
The impact of elevated C-reactive protein level on the prognosis for oro-hypopharynx cancer patients treated with radiotherapy. ( 29259311 )
2017
32
Persistent Tracheostomy after Organ Preservation Protocol in Patients Treated for Larynx and Hypopharynx Cancer. ( 29018502 )
2017
33
Downregulation of Calcium-Binding Protein S100A9 Inhibits Hypopharyngeal Cancer Cell Proliferation and Invasion Ability Through Inactivation of NF-I_B Signaling. ( 28276321 )
2017
34
A case of adult congenital laryngeal cleft asymptomatic until hypopharynx cancer treatment. ( 28943051 )
2017
35
Down syndrome critical region 1 positively correlates with angiogenesis in hypopharyngeal cancer. ( 27922696 )
2017
36
Frequent aberrant p53 and Fhit expression in endoscopically resected superficial hypopharyngeal cancer and esophageal cancer. ( 28693209 )
2017
37
Transoral robotic total laryngopharyngectomy and free jejunal flap reconstruction for hypopharyngeal cancer. ( 28720420 )
2017
38
Application of Ultrasound-guided Core Needle Biopsy in the Diagnosis of T3 or T4 Stage Laryngeal and Hypopharyngeal Cancer. ( 28739753 )
2017
39
Use of the liver maximum function capacity test (LiMAx) for the management of liver resection in cirrhosis - A case of hypopharyngeal cancer liver metastasis. ( 28841541 )
2017
40
Clinicopathologic Findings and Treatment Outcome of Laryngectomized Patients with Laryngeal Cancer and Hypopharyngeal Cancer: An Experience in Thailand ( 28843218 )
2017
41
Anticancer Effects of Colchicine on Hypopharyngeal Cancer. ( 29061810 )
2017
42
Different Response to Nivolumab in a Patient with Synchronous Double Primary Carcinomas of Hypopharyngeal Cancer and Non-Small-Cell Lung Cancer. ( 29070993 )
2017
43
A modified endoscopic submucosal dissection for a superficial hypopharyngeal cancer: a case report and technical discussion. ( 29110635 )
2017
44
E26 Transformation-Specific Transcription Factor ETS2 as an Oncogene Promotes the Progression of Hypopharyngeal Cancer. ( 29111780 )
2017
45
Lentivirus-mediated RNA interference inhibits the tumorigenicity of cluster of differentiation 44+ tumor cells in hypopharyngeal cancer. ( 29113169 )
2017
46
The Second-Look Procedure for Transoral Videolaryngoscopic Surgery for T1 and T2 Laryngeal, Oropharyngeal, and Hypopharyngeal Cancer Patients: Protocol for a Nonrandomized Clinical Trial. ( 29208591 )
2017
47
Clinicopathological factors influencing the outcomes of surgical treatment in patients with T4a hypopharyngeal cancer. ( 29284434 )
2017
48
Impact of the early detection of esophageal neoplasms in hypopharyngeal cancer patients treated with concurrent chemoradiotherapy. ( 25359448 )
2017
49
Comparison of Salvage Total Pharyngolaryngectomy and Cervical Esophagectomy Between Hypopharyngeal Cancer and Cervical Esophageal Cancer. ( 27714538 )
2017
50
Comparison of the outcomes of free jejunal flap reconstructions of pharyngoesophageal defects in hypopharyngeal cancer and corrosive injury patients. ( 27880017 )
2017

Variations for Hypopharynx Cancer

Expression for Hypopharynx Cancer

Search GEO for disease gene expression data for Hypopharynx Cancer.

Pathways for Hypopharynx Cancer

Pathways related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
9.77 ADH1B NME1

GO Terms for Hypopharynx Cancer

Biological processes related to Hypopharynx Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to cAMP GO:0051591 8.62 AREG NME1

Sources for Hypopharynx Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....